Receiving a notice from the NYSE for not meeting continued listing standards is a significant regulatory issue that can lead to negative investor sentiment and a decrease in stock price. The direct mention of Amwell (AMWL) in relation to this notice makes it highly relevant and important for investors, with a high confidence in the potential negative short-term impact on the stock.